Xeljanz XR 11 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F5F9B
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,833
Award facts
- Contract value 100% obligated
- $19,833.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19.8K delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on January 22, 2026, with completion scheduled for January 23, 2026. This non-competitive, firm fixed-price delivery order represents a task order issued against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., a leading pharmaceutical distributor that supplies critical medical products to federal government healthcare systems, including military treatment facilities and veteran healthcare programs.
XELJANZ XR is a branded immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. As the prime contractor under the DLA's global pharmaceutical support vehicle, AmerisourceBergen leverages its comprehensive supply chain capabilities to fulfill delivery orders for specialty medications and generic pharmaceuticals across multiple therapeutic domains. The DLA Troop Support Medical contract vehicle enables efficient procurement of essential pharmaceutical commodities to support military healthcare operations worldwide. This award reflects continued reliance on AmerisourceBergen's established capabilities to deliver brand-name prescription medications to federal medical systems on a firm fixed-price basis.
Quick answers
Who was awarded contract SPE2DR26F5F9B?
SPE2DR26F5F9B was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26F5F9B worth?
The government has obligated $19,833 on SPE2DR26F5F9B.
Is contract SPE2DR26F5F9B an order under another contract?
Yes. SPE2DR26F5F9B is a delivery order under SPE2DR25D3306, an indefinite delivery contract.
Was contract SPE2DR26F5F9B competed?
The extent of competition for SPE2DR26F5F9B was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award